Seres therapeutics enters into memorandum of understanding for vowst™ asset sale to nestlÉ health science

Seres anticipates capital infusions, including an upfront payment, enabling the company to fully retire its debt and extend its cash runway into q4 2025, pending deal closure and subject to performance under a transition services agreement
MCRB Ratings Summary
MCRB Quant Ranking